Welcome to our dedicated page for Lantheus Holdings news (Ticker: LNTH), a resource for investors and traders seeking the latest updates and insights on Lantheus Holdings stock.
Lantheus Holdings, Inc. (NASDAQ: LNTH) is a leading radiopharmaceutical-focused company, dedicated to the development, manufacture, and commercialization of innovative diagnostic imaging agents and products. Headquartered in North Billerica, Massachusetts, and with additional offices in Puerto Rico and Canada, Lantheus has been a pivotal player in the medical imaging industry for over 65 years.
The company's primary subsidiary, Lantheus Medical Imaging, Inc. (LMI), specializes in diagnostic imaging solutions primarily for cardiovascular diseases. Key products include the echocardiography contrast agent DEFINITY® Vial, the technetium-based generator TechneLite®, and the inhaled radiopharmaceutical imaging agent Xenon Xe 133 Gas for lung imaging.
Lantheus is organized into three main business units: Precision Diagnostics, Radiopharmaceutical Oncology, and Strategic Partnerships and Other Revenue. Precision Diagnostics focuses on products that assist healthcare professionals in detecting and monitoring diseases, particularly in cardiology. Radiopharmaceutical Oncology offers diagnostics and therapeutic solutions that help healthcare providers manage cancer. Through its Strategic Partnerships, Lantheus collaborates to advance precision medicine using biomarkers and digital solutions.
Recent achievements include strategic transactions to enhance their pipeline for neuroendocrine tumors and prostate cancer. Lantheus has partnered with Perspective Therapeutics, which has developed a best-in-class alpha therapy platform, enabling Lantheus to expand its pipeline into promising alpha therapies.
Financially, Lantheus has shown robust performance. The company reported record revenues of $1.3 billion for the full year 2023, marking a 38.6% increase from 2022. This growth was driven by the successful commercialization of innovative products and strategic acquisitions.
In the Radiopharmaceutical Oncology space, the company’s Abbreviated New Drug Application (ANDA) for Lutetium Lu 177 Dotatate has been accepted by the FDA. This product is intended for treating somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs).
Lantheus continues to drive innovation and growth through its robust pipeline and strategic collaborations. Recent leadership changes have positioned the company for its next phase of growth, with Brian Markison taking over as CEO from March 2024, following the successful tenure of Mary Anne Heino.
For ongoing updates and more information, visit their website at www.lantheus.com.
Lantheus Holdings (NASDAQ: LNTH) reported strong Q2 2024 financial results with worldwide revenue of $394.1 million, up 22.5% year-over-year. Key highlights include:
- PYLARIFY sales reached $273.3 million, up 29.8%
- DEFINITY sales grew 10.7% to $78.1 million
- Adjusted EPS increased 16.4% to $1.80
- Cash and equivalents grew to $757.0 million
The company completed three strategic transactions to expand its innovative pipeline, including acquisitions in Alzheimer's disease and oncology. Lantheus maintains its full-year 2024 revenue guidance but updated EPS guidance due to these strategic investments.
Lantheus Holdings (NASDAQ: LNTH) has announced its upcoming second quarter 2024 earnings conference call and webcast, scheduled for July 31, 2024, at 8:00 a.m. Eastern Time. The event will provide an opportunity for stakeholders to learn about the company's financial and operating results for Q2 2024. Participants are encouraged to register online at the investor relations website, preferably fifteen minutes before the start time to avoid delays. A replay of the webcast will be available approximately two hours after completion and will remain archived on the same web page for at least 30 days.
Lantheus Holdings (NASDAQ: LNTH) has acquired Meilleur Technologies, Inc., gaining worldwide exclusive rights to NAV-4694, a Phase 3 ß amyloid PET imaging agent for Alzheimer's disease. This acquisition expands Lantheus' Alzheimer's diagnostic portfolio, complementing their existing tau-targeting agent MK-6240. The move aligns with updated NIA-AA guidelines recommending biomarkers for Alzheimer's diagnosis.
The deal involves an upfront payment, potential milestone payments, and royalties. Lantheus aims to advance NAV-4694 through pivotal trials and commercialization. With nearly 12 million Americans living with mild cognitive impairment or Alzheimer's, and projections of over 20 million by 2050, this acquisition strengthens Lantheus' position in the growing neurology market.
Lantheus Holdings announced its support for the Centers for Medicare & Medicaid Services' (CMS) proposed 2025 Medicare Hospital Outpatient Prospective Payment System (OPPS) Rule, which aims to enhance payment for specialized diagnostic radiopharmaceuticals. CMS proposes separate payments for diagnostic radiopharmaceuticals costing over $630 per day, including Lantheus' PYLARIFY, instead of bundling these costs into nuclear medicine tests. The proposed rule includes a 60-day comment period ending September 9, 2024, with the final rule to be issued in early November and effective January 1, 2025. CEO Brian Markison highlighted the importance of equitable access to diagnostic radiopharmaceuticals for better patient outcomes.
Lantheus has appointed Jamie Spaeth as Chief People Officer, effective July 8, 2024. Ms. Spaeth joins the executive team, bringing nearly 20 years of HR experience in the biotech and pharma industries. Most recently, she served as Chief People Officer at Corium, a biopharmaceutical company.
Her responsibilities will include fostering a collaborative culture and supporting talent development to enhance Lantheus' strategy as a leading radiopharmaceutical-focused company. Ms. Spaeth's background includes roles at Sage Therapeutics and Shire, and she holds degrees in Hospitality and Tourism Management and Human Resources.
The addition of Ms. Spaeth is expected to strengthen Lantheus' leadership and support its mission of delivering better patient outcomes.
Lantheus Holdings, a leader in radiopharmaceuticals, has acquired global rights to Life Molecular Imaging's RM2, targeting the gastrin-releasing peptide receptor (GRPR) for prostate and breast cancers. The acquisition is valued at $35 million upfront with additional regulatory milestone payments and royalties. This deal enhances Lantheus' prostate cancer portfolio and introduces a new pipeline for breast and other cancers. RM2, including the radiotherapeutic 177Lu-DOTA-RM2 and the radiodiagnostic 68Ga-DOTA-RM2, has demonstrated favorable safety and dose-dependent efficacy. Lantheus plans to initiate a Phase 1/2a study in 2025, aiming to expand access to radiotheranostics for patients not suitable for PSMA-targeted therapies.
Lantheus has announced that its AI-enabled aPROMISE software is now available on Siemens Healthineers’ syngo.via platform. The integration will be demonstrated at the SNMMI annual meeting in Toronto from June 8-11, 2024. aPROMISE is FDA-cleared software designed to analyze PSMA PET/CT images, providing quantitative data on disease burden, which aids in patient selection and monitoring for PSMA-targeted therapies. The availability on Siemens' platform aims to enhance clinical workflows across PET sites in the U.S.
Clinical studies have shown that aPROMISE supports patient selection for PSMA radioligand therapy and automates response monitoring over time. The software will be accessible via Siemens' OpenApps Digital Marketplace, facilitating advanced visualization and analysis in nuclear medicine.
Lantheus, a leading radiopharmaceutical company, will present at the William Blair 44th Annual Growth Stock Conference. Paul Blanchfield, President of Lantheus, will deliver the presentation at 2:40 p.m. CT on June 4, 2024. Interested parties can access a live webcast or a replay on the company's website for at least 30 days following the event. This announcement highlights Lantheus' commitment to engaging with investors and sharing its growth strategies.
Lantheus (NASDAQ: LNTH) has announced the appointment of two new executives to accelerate its innovation efforts. Dr. Jeffrey S. Humphrey will join as Chief Medical Officer (CMO) and Dr. Jean-Claude Provost will take on the role of Chief Science Officer (CSO), both starting on May 28, 2024. Dr. Humphrey brings over 30 years of experience in clinical oncology and drug development, having worked with global pharmaceutical companies like Bayer and Pfizer. As CMO, he will oversee research and development, clinical development, and regulatory affairs. Dr. Provost, with a similar tenure of over 30 years, will focus on enhancing Lantheus’ pipeline and capabilities. Both appointees are expected to contribute significantly to Lantheus’ mission of better patient outcomes through innovative diagnostics and therapeutics.
Lantheus Holdings, Inc. reported a 23.0% increase in worldwide revenue to $370.0 million for the first quarter of 2024 compared to the same period in 2023. The company achieved a GAAP fully diluted net income per share of $1.87, a significant improvement from a net loss per share of $0.04 in the first quarter of 2023. Adjusted fully diluted net income per share reached $1.69, up from $1.47 in the previous year. Lantheus also enhanced its full-year 2024 net revenue and earnings guidance while providing guidance for the second quarter of 2024. The company's strong financial position and market-leading commercial portfolio set the stage for continued growth through investments in current business operations, business development, and M&A opportunities in diagnostics and therapeutics.
FAQ
What is the current stock price of Lantheus Holdings (LNTH)?
What is the market cap of Lantheus Holdings (LNTH)?
What does Lantheus Holdings, Inc. specialize in?
What are some key products of Lantheus?
Where is Lantheus Holdings headquartered?
What are the core business units of Lantheus?
Who is the current CEO of Lantheus Holdings?
What recent achievements has Lantheus accomplished?
What financial growth did Lantheus achieve in 2023?
What is the significance of DEFINITY® Vial?
What types of diseases does Lantheus focus on in their diagnostics?
How does Lantheus contribute to precision medicine?
